LEXINGTON, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (ACUS.PK) today announced that it had completed the Marketing Authorisation Application (MAA) dossier for its lead product candidate, Imagify™ (Perflubutane Polymer Microspheres) for Injectable Suspension, and is now starting the process of filing the MAA dossier with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU). The company has also secured an additional $8 million of debt financing this year, following stockholder approval of a reverse stock split in early 2012.
